Thomas Steyer’s Guardant Health GH Stock Holding History

Thomas Steyer’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.3M	Buy	322,200 +314,200	+3,928%	+$34.2M	0.22%	39
2026 Q1	$739K	Sell	8,000 -101,000	-93%	-$10.1M	﹤0.01%	102
2025 Q4	$11.1M	Buy	109,000 +101,000	+1,263%	+$9.04M	0.05%	72
2025 Q3	$500K	Hold	8,000	–	–	﹤0.01%	91
2025 Q2	$416K	Buy	+8,000	New	+$357K	﹤0.01%	96

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Thomas Steyer's GH Position: Q2 2026 in Review

Thomas Steyer increased its Guardant Health (GH) stake by 3,928% in Q2 2026, buying an estimated $34.2M and bringing the position to 322,200 shares worth $48.3M. The position accounts for 0.22% of the portfolio, ranked #39.

Thomas Steyer first reported a position in GH in Q2 2025 and has held it in 5 quarters since. 595 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Thomas Steyer held 322,200 shares of Guardant Health worth $48.3M as of Q2 2026.
Thomas Steyer bought 314,200 Guardant Health shares in Q2 2026, an estimated $34.2M.
Guardant Health made up 0.22% of Thomas Steyer's portfolio in Q2 2026, its #39 holding.
Thomas Steyer first reported a position in Guardant Health in Q2 2025 and has held it in 5 quarters since.
595 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.